Zhanggui Wu

Title: Zhanggui Wu and Combination Cancer Therapy Using a CHK Inhibitor.

Introduction

Zhanggui Wu is an inventor associated with Shanghai Huayu Biotechnology Co. Ltd. His listed location is Brookline, WA (US). His patent work concerns a combination cancer therapy that pairs a checkpoint kinase (CHK) inhibitor with a poly (ADP)-ribose polymerase (PARP) inhibitor.

Latest Patents

Wu is credited with 1 patent, titled “Combination Cancer Therapy Using CHK Inhibitor.” The patent describes methods for treating breast, colon, ovarian, or pancreatic cancer by administering a compound of formula I, or a pharmaceutically acceptable salt of that compound, together with a PARP inhibitor. The compound of formula I acts as a CHK inhibitor. The disclosed combination is intended to produce synergistic anti-tumor effects, including greater inhibition of tumor-cell growth at reduced effective concentrations. The patent also describes pharmaceutically acceptable compositions containing the CHK inhibitor and a PARP inhibitor.

Career Highlights

Wu’s listed invention focuses on combining targeted cancer therapies to enhance anti-tumor activity. The disclosed approach covers several cancer types and includes both treatment methods and pharmaceutical compositions.

Collaborations

Wu is listed as a coworker of Fan Wu. His company affiliation is Shanghai Huayu Biotechnology Co. Ltd.

Conclusion

Zhanggui Wu’s listed patent centers on combining a CHK inhibitor with a PARP inhibitor as a potential strategy for treating several cancers and improving tumor-growth inhibition.